Conexeu Completes Preclinical Study for New Collagen Volume Restoration Platform

Conexeu Sciences completed its 12-month preclinical P.R.O.O.F study for its CXU flowable collagen-based tissue-restoration platform, showing successful tissue restoration in both a small-volume facial cheek model and a large-volume 200cc-equivalent model. The platform met mechanical performance benchmarks for injectability and volumizing, which positions it to target the growing tissue-restoration market gap. This gap, driven largely by rapid volume loss from GLP-1 weight-loss drugs, is projected to reach between 0.7 billion and 2.0 billion dollars by 2030. Conexeu holds patents across more than 40 jurisdictions, including the U.S., EU, Japan, and Australia. For your practice, this signal suggests a viable, large-volume collagen option is moving closer to market. Conexeu plans to submit a predicate-based 510(k) FDA application for its lead wound care device in the first quarter of 2027, utilizing a 90-day review target, which will establish the regulatory foundation for its aesthetic rollouts.

Source: Conexeu Sciences, https://www.globenewswire.com/news-release/2026/07/07/3335894/0/en/Conexeu-Completes-12-Month-Preclinical-P-R-O-O-F-Study-Supporting-Its-Intended-Move-Into-the-11-Billion-Medical-Aesthetics-Market-as-a-Platform.html